Research Highlight Published: February 2007 Long-term α-adrenergic-antagonist treatment alleviates symptoms of CP/CPPS Nature Clinical Practice Urology 4, 65–66 (2007) Cite this article ...

A number of mechanisms explaining the variable effects of different β-blockers in HF patients have been proposed (e.g., variability in heart rate responses, modulation of systemic neurohormonal ...

APD418 is a first-in-class β3 adrenergic receptor selective antagonist and cardiac myotrope that is expected to improve cardiac contractility with little effect on heart rate, blood pressure and ...

Scientists have shown the efficacy of a new non-opioid oral painkiller known as ADRIANA, the world's first selective α2B-adrenoceptor antagonist – a receptor subtype not previously targeted for ...

March 16, 2021 Drugs such as beta-adrenergic antagonists (beta blockers) have been linked to a range of adverse effects, including depression.

Alpha adrenergic receptors are concentrated in the lower ureter but they exist along the entire ureter, the investigators highlighted. Stone passage occurred at 8.8 and 13.3 days on average in the ...

Proceedings of the National Academy of Sciences of the United States of America, Vol. 77, No. 11, [Part 2: Biological Sciences] (Nov., 1980), pp. 6401-6405 (5 pages) A fluorescence receptor binding ...

About Phentolamine Ophthalmic Solution 0.75% Phentolamine Ophthalmic Solution 0.75% is a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, administered as an eye drop.

Ryzumvi ™ (phentolamine ophthalmic solution, 0.75%) is now available for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists (eg, phenylephrine) or ...